SCHEMBL26348347

SCHEMBL26348347

CCS(=O)(=O)N(F)c1cccc(C)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.46
POLB P06746 3/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 5/20 0.41
TP53 P04637 4/20 0.41
NPC1 O15118 1/20 0.41
GPX4 P36969 1/20 0.41
RAB9A P51151 1/20 0.41
PAX8 Q06710 1/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
GLA P06280 2/20 0.40
ALOX15 P16050 1/20 0.40
MAPT P10636 2/20 0.39
KMT2A Q03164 1/20 0.39
ACHE P22303 1/20 0.38
GAA P10253 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10211704 0.80 ALDH1A1 (0.51) RECQLPOLBLMNAHTTALDH1A1
SCHEMBL8391381 0.73 ALDH1A1 (0.45) RECQLLMNAHTTALDH1A1TP53
SCHEMBL30124196 0.73 ALDH1A1 (0.45) RECQLLMNAHTTALDH1A1TP53
SCHEMBL457496 0.72 ALDH1A1 (0.61) RECQLLMNAHTTALDH1A1TP53
SCHEMBL30565134 0.72 ALDH1A1 (0.61) RECQLLMNAHTTALDH1A1TP53
SCHEMBL728283 0.72 ACHE (0.52) POLBLMNAHTTALDH1A1TP53
SCHEMBL4518120 0.72 ACHE (0.52) POLBLMNAHTTALDH1A1TP53
SCHEMBL28092078 0.72 ACHE (0.52) RECQLPOLBLMNAHTTALDH1A1
SCHEMBL21065775 0.72 ALDH1A1 (0.44) RECQLLMNAHTTALDH1A1TP53
Lithium Ion SCHEMBL19732619 0.72 ALDH1A1 (0.44) RECQLLMNAHTTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303501-A1 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303501-A1 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME ABL1, ABL2, MUSK RECQL 3773/4885POLB 3784/4885LMNA 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.